公开(公告)号：US20220411522A1

公开(公告)日：2022-12-29

申请号：US17684238

申请日：2022-03-01

申请人： GENMAB B.V.

发明人： Frank BEURSKENS ,  Marije OVERDIJK ,  Rob DE JONG ,  David SATIJN ,  Kristin STRUMANE ,  Janine SCHUURMAN ,  Paul PARREN

IPC分类号： C07K16/28 ,  C07K16/30 ,  A61P35/00 ,  C12N15/62

摘要： The present invention relates to monospecific or bispecific antibody molecules that specifically bind antigens of Death Receptors, which are members of the tumor necrosis factor (TNF) receptor Superfamily (TNFR-SF) with an intracellular death domain. The invention relates in particular to antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after target binding. The invention further relates to a combination of antibody molecules binding different epitopes on one or more specific Death Receptors. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.

公开(公告)号：US20150337049A1

公开(公告)日：2015-11-26

申请号：US14760157

申请日：2014-01-09

申请人： GENMAB B.V.

发明人： Aran Frank LABRIJN ,  Joyce MEESTERS ,  Joost J. NEIJSSEN ,  Edward Norbert VAN DEN BRINK ,  Janine SCHUURMAN ,  Paul PARREN

IPC分类号： C07K16/28

摘要： Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain. Furthermore, is described the uses and methods related to said proteins.

摘要翻译： 本文描述的是在第一和第二多肽链中的至少一个中包含氨基酸取代的蛋白质。 此外，描述了与所述蛋白质相关的用途和方法。

公开(公告)号：US20210324096A1

公开(公告)日：2021-10-21

申请号：US17108373

申请日：2020-12-01

申请人： GENMAB B.V.

发明人： Marije OVERDIJK ,  Kristin STRUMANE ,  Rik RADEMAKER ,  Esther BREIJ ,  Janine SCHUURMAN ,  Paul PARREN

IPC分类号： C07K16/28 ,  C07K16/30 ,  A61P35/00 ,  C12N15/62

摘要： The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signalling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.

公开(公告)号：US20210163619A1

公开(公告)日：2021-06-03

申请号：US16921154

申请日：2020-07-06

申请人： GENMAB B.V.

发明人： Paul PARREN ,  Frank BEURSKENS ,  Rob N. DE JONG ,  Aran Frank LABRIJN ,  Janine SCHUURMAN

IPC分类号： C07K16/28 ,  C07K16/36 ,  C07K16/00

摘要： Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.

公开(公告)号：US20190315877A1

公开(公告)日：2019-10-17

申请号：US16451714

申请日：2019-06-25

申请人： GENMAB B.V.

发明人： Marije OVERDIJK ,  Kristin STRUMANE ,  Rik RADEMAKER ,  Esther BREIJ ,  Janine SCHUURMAN ,  Paul PARREN

IPC分类号： C07K16/28 ,  C12N15/62 ,  C07K16/46 ,  C07K16/30 ,  A61P35/00

摘要： The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signaling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.

公开(公告)号：US20200181277A1

公开(公告)日：2020-06-11

申请号：US16482747

申请日：2018-02-12

申请人： GENMAB B.V.

发明人： Frank BEURSKENS ,  Marije OVERDIJK ,  Annieck M. DIKS ,  Rob DE JONG ,  Kristin STRUMANE ,  Janine SCHUURMAN ,  Paul PARREN

IPC分类号： C07K16/28 ,  C07K16/10

摘要： As described herein are polypeptides and antibodies having an Fc region and an antigen binding region where the Fc region has an Fc-Fc-enhancing mutation and a C1q binding-enhancing mutation providing for polypeptides or antibodies with increased CDC activity and/or agonistic activity.

公开(公告)号：US20190202926A1

公开(公告)日：2019-07-04

申请号：US15780285

申请日：2016-12-01

申请人： GENMAB B.V.

发明人： Frank BEURSKENS ,  Marije OVERDIJK ,  Rob DE JONG ,  David SATIJN ,  Kristin STRUMANE ,  Janine SCHUURMAN ,  Paul PARREN

IPC分类号： C07K16/28 ,  A61P35/00 ,  C07K16/30

CPC分类号： C07K16/2878 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/507 ,  A61P35/00 ,  C07K16/30 ,  C07K16/46 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/526 ,  C07K2317/73 ,  C07K2317/75 ,  C12N15/62

摘要： The present invention relates to monospecific or bispecific antibody molecules that specifically bind antigens of Death Receptors, which are members of the tumor necrosis factor (TNF) receptor Superfamily (TNFR-SF) with an intracellular death domain. The invention relates in particular to antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after target binding. The invention further relates to a combination of antibody molecules binding different epitopes on one or more specific Death Receptors. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.

公开(公告)号：US20220332801A1

公开(公告)日：2022-10-20

申请号：US17534712

申请日：2021-11-24

申请人： GENMAB B.V.

发明人： Annemarie KUIPERS ,  Kok VAN KESSEL ,  Frank BEURSKENS ,  Rob DE JONG ,  Kristin STRUMANE ,  Janine SCHUURMAN ,  Paul PARREN ,  Jos VAN STRIJP ,  Suzan ROOIJAKKERS

IPC分类号： C07K16/12 ,  A61P31/04

摘要： The present invention relates to antibody molecules that bind to Wall Teichoic Acid (WTA) or Capsular Polysaccharides (CP) such as Capsular Polysaccharides type 5 (CP5). The invention relates in particular to antibody molecules of the IgG isotype having a mutation in the Fc domain that enhances clustering of IgG molecules after target binding. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of infectious diseases using these compositions

公开(公告)号：US20190276549A1

公开(公告)日：2019-09-12

申请号：US16345044

申请日：2017-11-01

申请人： GENMAB B.V.

发明人： Rob DE JONG ,  Frank BEURSKENS ,  Marije OVERDIJK ,  Kristin STRUMANE ,  Janine SCHUURMAN ,  Paul PARREN

IPC分类号： C07K16/28 ,  A61P35/00 ,  A61P37/06 ,  A61P31/04 ,  A61P31/12 ,  A61P31/10

摘要： Described herein are polypeptides and antibodies comprising a variant Fc region. The variant Fc region provides for stabilized Fc-Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, while at the same time also having decreased complement-dependent cytotoxicity (CDC) and may also have decreased activation of other effector functions resulting from one or more amino acid modifications in the Fc region.

公开(公告)号：US20190144554A1

公开(公告)日：2019-05-16

申请号：US15780268

申请日：2016-12-01

申请人： GENMAB B.V.

发明人： Marije OVERDIJK ,  Kristin STRUMANE ,  Rik RADEMAKER ,  Esther BREIJ ,  Janine SCHUURMAN ,  Paul PARREN

IPC分类号： C07K16/28 ,  C07K16/46 ,  C12N15/62 ,  C07K16/30 ,  A61P35/00

摘要： The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signalling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.